Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 28

1.

Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis.

Sax PE, Islam R, Walensky RP, Losina E, Weinstein MC, Goldie SJ, Sadownik SN, Freedberg KA.

Clin Infect Dis. 2005 Nov 1;41(9):1316-23. Epub 2005 Sep 23.

PMID:
16206108
2.

Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012.

Flys T, Nissley DV, Claasen CW, Jones D, Shi C, Guay LA, Musoke P, Mmiro F, Strathern JN, Jackson JB, Eshleman JR, Eshleman SH.

J Infect Dis. 2005 Jul 1;192(1):24-9. Epub 2005 Jun 1.

PMID:
15942890
3.

A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study.

Torti C, Quiros-Roldan E, Regazzi M, De Luca A, Mazzotta F, Antinori A, Ladisa N, Micheli V, Orani A, Patroni A, Villani P, Lo Caputo S, Moretti F, Di Giambenedetto S, Castelnuovo F, Maggi P, Tinelli C, Carosi G; RADAR-MASTER Study Group..

Clin Infect Dis. 2005 Jun 15;40(12):1828-36. Epub 2005 May 12.

PMID:
15909273
4.

LigAmp for sensitive detection of single-nucleotide differences.

Shi C, Eshleman SH, Jones D, Fukushima N, Hua L, Parker AR, Yeo CJ, Hruban RH, Goggins MG, Eshleman JR.

Nat Methods. 2004 Nov;1(2):141-7. Epub 2004 Oct 21.

PMID:
15782177
5.

Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.

Loutfy MR, Raboud JM, Walmsley SL, Saskin R, Montaner JS, Hogg RS, Thompson CA, Harrigan PR.

Antivir Ther. 2004 Aug;9(4):595-602.

PMID:
15456091
6.

Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals.

Gallego O, Martin-Carbonero L, Aguero J, de Mendoza C, Corral A, Soriano V.

J Virol Methods. 2004 Oct;121(1):115-8.

PMID:
15350741
7.

Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects.

Swanstrom R, Bosch RJ, Katzenstein D, Cheng H, Jiang H, Hellmann N, Haubrich R, Fiscus SA, Fletcher CV, Acosta EP, Gulick RM; AIDS Clinical Trials Group Protocol 359 Team..

J Infect Dis. 2004 Sep 1;190(5):886-93. Epub 2004 Jul 23.

PMID:
15295692
8.

Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia.

Mackie N, Dustan S, McClure MO, Weber JN, Clarke JR.

J Virol Methods. 2004 Aug;119(2):73-8.

PMID:
15158587
9.

HIV-1 genotyping: comparison of two commercially available assays.

Stürmer M, Berger A, Preiser W.

Expert Rev Mol Diagn. 2004 May;4(3):281-91.

PMID:
15137896
10.

Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1.

Zhang H, Zhou Y, Alcock C, Kiefer T, Monie D, Siliciano J, Li Q, Pham P, Cofrancesco J, Persaud D, Siliciano RF.

J Virol. 2004 Feb;78(4):1718-29.

11.

Performance of the VERSANT HIV-1 resistance assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypes.

Derdelinckx I, Van Laethem K, Maes B, Schrooten Y, De Schouwer K, De Wit S, Fransen K, García Ribas S, Moutschen M, Vaira D, Zissis G, Van Ranst M, Van Wijngaerden E, Vandamme AM.

FEMS Immunol Med Microbiol. 2003 Nov 28;39(2):119-24.

12.

HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations.

Scudeller L, Torti C, Quiros-Roldan E, Patroni A, Lo Caputo S, Moretti F, Mazzotta F, Donati E, Vivarelli A, Carosi G; GenPheRex Group of the MASTER Cohort..

J Antimicrob Chemother. 2003 Nov;52(5):776-81. Epub 2003 Oct 16.

PMID:
14563897
13.

Comparison of nine resistance interpretation systems for HIV-1 genotyping.

Stürmer M, Doerr HW, Staszewski S, Preiser W.

Antivir Ther. 2003 Jun;8(3):239-44.

PMID:
12924541
14.

Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients.

Torti C, Quiros-Roldan E, Keulen W, Scudeller L, Lo Caputo S, Boucher C, Castelli F, Mazzotta F, Pierotti P, Been-Tiktak AM, Buccoliero G, De Gennaro M, Carosi G, Tinelli C; GenPherex Study Group of the MaSTeR Cohort..

J Infect Dis. 2003 Jul 15;188(2):194-201. Epub 2003 Jul 1.

PMID:
12854073
15.

Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial.

Mazzotta F, Lo Caputo S, Torti C, Tinelli C, Pierotti P, Castelli F, Lazzarin A, Angarano G, Maserati R, Gianotti N, Ladisa N, Quiros-Roldan E, Rinehart AR, Carosi G; Genotipo-Fenotipo di Resistenza (GenPheRex) Group of the Italian Management Standardizzato di Terapia Antiretrovirale (MASTER) Cohort..

J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):268-80.

PMID:
12626886
16.
17.

Implications of antiretroviral resistance on viral fitness.

Nijhuis M, Deeks S, Boucher C.

Curr Opin Infect Dis. 2001 Feb;14(1):23-8. Review.

PMID:
11979111
18.

Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program.

Schuurman R, Brambilla D, de Groot T, Huang D, Land S, Bremer J, Benders I, Boucher CA; ENVA Working Group..

AIDS Res Hum Retroviruses. 2002 Mar 1;18(4):243-8.

PMID:
11860670
19.

World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing.

Harrigan PR, Montaner JS, Wegner SA, Verbiest W, Miller V, Wood R, Larder BA.

AIDS. 2001 Sep 7;15(13):1671-7.

PMID:
11546942
20.

Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs.

Dunne AL, Mitchell FM, Coberly SK, Hellmann NS, Hoy J, Mijch A, Petropoulos CJ, Mills J, Crowe SM.

AIDS. 2001 Aug 17;15(12):1471-5.

PMID:
11504978

Supplemental Content

Support Center